Recruiting
Phase 2

Radiation Therapy

Sponsor:

University Health Network, Toronto

Code:

NCT06453486

Conditions

Locally Advanced Pancreatic Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

High dose radiation therapy

Study Details

Brief summary:

The goal of this clinical trial is to test the effect of high-dose radiation therapy after initial chemotherapy in patients with locally advanced pancreatic cancer. The main question it aims to answer is:

• For patients with locally advanced pancreatic cancer that responded to initial chemotherapy (stayed stable or decreased in size), will high-dose RT (radiation therapy) contribute to improving treatment outcomes, enhancing quality of life, or increasing overall survival rates?

Participants will:

  • Undergo an optional tumor biopsy.
  • Be treated with high dose radiation therapy.
  • Complete quality of life questionnaires.
  • Donate research blood samples.

Conditions

Locally Advanced Pancreatic Adenocarcinoma

Study ID

NCT06453486

Start date

Mar 12, 2025

Status verified date

Apr, 2026

Completion date

Apr, 2030

Anticipated

Primary completion date

Apr, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Have a histological or cytological diagnosis of LAPC.
  • Have pancreatic tumour <8.0 cm in greatest axial dimension at the time of treatment planning but final determination of eligibility will be based upon satisfying the radiation normal tissue constraints.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤1 (Karnofsky ≥70%).
  • Life expectancy of greater than 6 months, as judged by the investigator.
  • Patients must have had prior first-line chemotherapy for this cancer for at least 16 weeks without clinical or radiographic progression. There should be a washout of at least 2 weeks from first-line chemotherapy and start of therapy on clinical trial.
  • Ability to understand and willing to sign a written informed consent document.
  • Women must not be pregnant or breast-feeding. All females of child bearing potential must have a serum or urine pregnancy test to rule out pregnancy within 4 weeks prior to registration. All breastfeeding women should discontinue breastfeeding prior to study registration.

Exclusion Criteria:

  • Metastatic disease at the time of registration
  • Age<18.
  • Patients who have had prior systemic treatment (chemotherapy or any other anti-cancer agent) in the metastatic setting.
  • Prior radiotherapy to the upper abdomen region that would result in overlap of RT volume for the current study.
  • Patients who are currently on anti-cancer treatment including chemotherapy.
  • Uncontrolled inter-current illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant and breastfeeding women.
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
  • Individuals with a history of a different malignancy except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
  • Individuals with diseases precluding high dose ablative RT (e.g. scleroderma, gastric or bowel ulceration or perforation within the planned irradiated volume)
  • Patient should NOT be treated with MR-Linac if they have any contraindications for MRI, including presence of a heart pacemaker, (ferrous) metallic foreign bodies, and severe claustrophobia. Patients will be screened and excluded from the study if they have previous anaphylactic reactions to gadolinium and severe kidney disease (glomerular filtration rate < 30mL/min/1.73m2) or acute kidney disease.

Study Design

Enrollment

43 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Interventions

High dose radiation therapy

High dose radiation refers to the administration of a concentrated beam of radiation to target and treat the tumor. High dose radiation therapy typically involves delivering radiation in fractions over a set period. For instance, options such as:

  • 50Gy/5Fx: 50 Gray delivered over 5 fractions, administered every other day over 2 weeks.
  • 67.5Gy/15Fx: 67.5 Gray delivered over 15 fractions, administered once a day over 3 weeks.
  • 75Gy/25Fx: 75 Gray delivered over 25 fractions, administered once a day over 5 weeks.

These numbers denote the total dose of radiation (in Gray, abbreviated as Gy) delivered over a specific number of fractions (abbreviated as Fx), and the respective time frames for administration. The selection of radiation therapy (RT) dose levels for participants is guided by the expertise and evaluation of the radiation oncologist.

Primary outcome measure

  • Overall survival (OS) [ Time Frame: 5 years ]

Central Contacts and Locations

Central contacts

Anna Dodd

647-539-6498Anna.Dodd@uhn.ca

Locations

Princess Margaret Cancer Centre

Recruiting

Toronto, Ontario, Canada, M5G 2M9

Contacts

Anna Dodd

647-539-6498Anna.Dodd@uhn.ca

McGill University Health Centre

Recruiting

Montreal, Quebec, Canada, H4A 3J1

Contacts

Adeline Cuggia

514-934-1934cancer.pancreas@muhc.mcgill.ca

More Information

Sponsor

University Health Network, Toronto

Last update posted

Apr 16, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University Health Network, Toronto on 2026-04-16.